Join DeepSense on January 17th at 12:30 pm AT for the Ocean AI Workshop with Canada’s Ocean Supercluster. The Supercluster recently launched an AI Ocean 2024 call for proposals to invest in the development of commercial AI projects. Artificial intelligence (AI) has significant potential for profound impacts on the future, health, and prosperity of the world’s ocean. Every global opportunity in the blue economy will be influenced by the increasing use of AI in operational decision-making. AI adoption will be a key enabler of growth to the future ocean economy. This one-hour workshop is designed to provide potential project partners with support to address gaps ocean companies may have in developing AI solutions. During the session companies will have the opportunity to meet with the DeepSense team to explore possible support for their AI endeavors. Breakout rooms will be provided for participants to self-select into any of the following groups and get the support they need: Breakout Room 1: AI Expertise for Existing Solutions Company has an existing solution in mind but has specific challenges (lack of technical experience) in implementing the AI in their current infrastructure. Breakout Room 2: Understanding Data and Options Company has their own data and are looking to maximize […]

  In the life sciences industry, IP is everything. Join us for an in-depth look at IP for life sciences start-ups with Dr. Chris Barden, CEO of US/Canadian pharma company Treventis Corp. and a registered U.S. Patent Agent. Dr. Barden will share “lessons learned” navigating the regulatory system in the U.S. and the EU and how he built a robust IP portfolio. At Treventis he leads a team of scientists working on disease-modifying therapeutics against protein misfolding diseases such as Alzheimer’s (the subject of a $370MM partnership with Takeda). Topics covered: When and when NOT to Patent U.S. Clinical Research Regulations Protecting Trade Secrets Leveraging licensing opportunities Tactics and Best Practices About Dr. Chris Barden Chris is a serial entrepreneur and inventor (80+ issued patents) with R&D, operating, dealmaking, and other executive experience in several pharmaceutical, medical device, and diagnostic start-ups. At Treventis, he leads a team of scientists working to design disease-modifying therapeutics against protein misfolding diseases such as Alzheimer’s (the subject of a $370MM partnership with Takeda). In his IP consulting practice, Chris brings a founder’s perspective to the complicated landscape of patent rules and regulations, helping companies understand how to best position their IP for commercial success, […]